CALGARY, Alberta--(BUSINESS WIRE)--June 9, 2005--Resverlogix Corp. (TSX:RVX) (“Resverlogix”), is pleased to update the progress of our previously announced “Request for Proposal Process” (RFP). Resverlogix has now completed the second stage of the process, the scientific review and conditional terms portion, and can announce that is has narrowed its candidate selection from seven to two. “We are very pleased with the results of our last several months work. We had the opportunity to exchange perspectives from these high level scientific reviews of our NEXVAS(TM) project, witnessing first hand the internal corporate cultures of seven differing major pharmaceutical companies and selectively narrow the field of whom we feel is best suited to help advance our NEXVAS(TM) program.” stated Donald J. McCaffrey President and CEO of Resverlogix. “Although we have narrowed our preference down to two specific groups we are maintaining communications with the other firms until such time as we can officially conclude the legal aspects of a term sheet. We are pleased with our progress to date and confident that upon our acceptance of a formal agreement we will surpass our set terms.”
